Effect of Early revascularization versus delayed revascularization versus medical therapy on inpatient mortality in patients with non ST elevation MI in.

Slides:



Advertisements
Similar presentations
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Advertisements

Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
New Treatment Advances in Acute Coronary Syndrome.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Prospective, Randomized Evaluation of Immediate Versus Deferred Angioplasty in Patients with High Risk Acute Coronary Syndromes RK Riezebos 1, E Ronner.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
RITA-3 ESC 4 th September 2005 The impact of underlying risk and gender on the benefit of early intervention in non-ST elevation acute coronary syndrome.
Ramin Ebrahimi, MD University of California Los Angeles/ Greater Los Angeles VA Medical Center Implications of Preoperative Thienopyridine Use Prior to.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Antiplatelet Interventions in Acute Coronary Syndromes.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
The Benefit of an Invasive Strategy in Women Versus Men with Non-ST-Elevation ACS: A Collaborative Meta-Analysis of Randomized Trials Michelle O’Donoghue,
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Eptifibatide is Noninferior to Abciximab in Primary PCI – Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry) Axel Åkerblom,
Invasive Versus Conservative Strategy in Patients Aged 80 years or Older with NSTEMI or Unstable Angina(After Eighty study) Nicolai Tegn, Michael Abdelnoor,
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Benefit of Early Invasive Therapy in Acute Coronary.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Small molecule glycoprotein IIb/IIIa receptor inhibitors.
Josephine Mak Waikato Cardiothoracic Unit Journal Club
The American College of Cardiology Presented by Dr. Adnan Kastrati
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
This series of slides highlights a report on a symposium at the European Society of Cardiology Congress held in Munich, Germany from August 28 to September.
Section F: Clinical guidelines
Section D: Clinical trial update: GP IIb/IIIa inhibition
Invasive versus conservative treatment in unstable coronary syndromes
TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
% Heparin + GPI IIb/IIIa Bivalirudin +
The European Society of Cardiology Presented by RJ De Winter
American College of Cardiology Presented by Dr. Michel R. Le May
Global Registry of Acute Coronary Events: GRACE
Implications of Preoperative Thienopyridine Use
What oral antiplatelet therapy would you choose?
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
Advantages of an early invasive approach in acute coronary syndromes
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
C-3. Clinical trial updates: GP IIb/IIIa inhibitors
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Effect of Early revascularization versus delayed revascularization versus medical therapy on inpatient mortality in patients with non ST elevation MI in a community hospital Setting Owais Jeelani,MBBS Mentor:Dr.A.Herle,MD,FACC

Background Coronary heart disease is the leading cause of death in the United States, with myocardial infarction a common manifestation of this disease. Of all patients having a myocardial infarction, 25 to 35% die before receiving medical attention, most often from ventricular fibrillation. For those who reach a medical facility, the prognosis is considerably better and has improved over the years: in-hospital mortality rates fell from 11.2% in 1990 to 9.4% in 1999

Background In 2006, approximately 1.2 million Americans sustained a myocardial infarction. Of these, two third had a myocardial infarction without ST- segment elevation

Background Randomized trials have shown that a routine invasive strategy is beneficial in high-risk patients with acute coronary syndromes.

Non-ST Elevation ACS Generally caused by partially occlusive, platelet-rich thrombus Unobstructed lumen thrombus Results from cross-linking of fibrinogen by platelet GP IIb- IIIa receptors at sites of plaque rupture platelet fibrinogen Ruptured plaque GP IIb-IIIa Artery wall

Background In patients with myocardial infarction with ST-segment elevation, in which the infarct-related artery is usually occluded and there is ongoing transmural ischemia, it is well established that the earlier primary percutaneous coronary intervention can be performed, the lower the mortality. By contrast, in patients with acute coronary syndromes without ST-segment elevation (including unstable angina and myocardial infarction), the culprit artery is often patent, there is usually no ongoing transmural ischemia, and the patient may have a good response to initial medical treatment.

Background Although meta-analyses of previous randomized trials that compared an invasive strategy with a conservative strategy in patients with acute coronary syndromes have shown a benefit for an invasive strategy, the timing of angiography in the invasive-strategy group of these previous studies ranged from as early as 19 hours after randomization in one large trial to as late as 96 hours in another large trial.

Invasive vs. Conservative Strategy for UA/NSTEMI – All Studies TIMI IIIB Conservative Invasive VANQWISH MATE FRISC II TACTICS- TIMI 18 VINO RITA-3 # Pts: TRUCS ISAR-COOL ICTUS

Background Given this wide variation in the timing, there remains substantial uncertainty regarding the optimal timing for intervention in such patients. Small, randomized trials comparing early intervention with delayed intervention have generated conflicting results.

Background Although some observational analyses have suggested that earlier intervention, as compared with delayed intervention, may reduce events, others have suggested that outcomes appear to be similar between the two approaches. Also, there has been a suggestion of a hazard associated with routine early intervention.

Study Objective Primary endpoint: -Is early revascularization better than delayed revascularization or Medical therapy alone in reducing in hospital mortality in Patients with non ST elevation MI in a community care setting?

Secondary endpoint What is the relative mortality of NSTEMI patients undergoing early revascularization vs delayed revascularization vs medical therapy alone? What is the relative length of hospital stay in the three groups studied? What percentage of coronary angiography patients actually underwent intervention (PCI or CABG)?

Methods Retrospective Data Analysis of patients at Mercy Hospital who have documented non ST elevation MI from June 2008 to June 2009 Institutional Review Board approval through the Catholic Health System 383 out of 591 patients reviewed were enrolled in the study after meeting the inclusion criteria

Inclusion criteria Based on ICD Coding Patients with non ST elevation MI with chest pain at rest, lasting > 30 minutes and non- responding to sublingual nitroglycerin tablets in addition to elevated troponins greater than or equal to 0.1.

Exclusion criteria Patients with ST elevation MI not fulfilling the above criteria. Patients with MI not fulfilling the above inclusion criteria

Analysis of Data Mortality odds ratios used for the comparison of proportion of deaths in each arm (primary end point). Length of Stay comparison evaluated by mean number of days along with 95% confidence interval standard deviations. paired t-test with a p-value of <0.05 deemed statistically significant

BASELINE CHARACTERISTICS Variable Early Revascularization Delayed Revascularization P value Medical Management P value 2 Demographic Characteristics Age Male Sex(%) Medical history(%) Previous MI Diabetes Ischemic changes on EKG Previous Coronary Procedure PCI CABG

Primary Outcome Characteristic No of Patients Revascul arized % Medical % Odd’s ratio for event(95%CI)P-Value for Interaction Overall ( to ) Age < ( to ) > ( to ) Sex Female ( to ) Male ( to ) ST segment deviation No ( to 1.487) Yes ( to ) More than 3 Risk Factors No ( to ) Yes ( to 0.261)

Results Primary End-Point –There is statistically significant difference in in- hospital mortality between patients treated with revascularization versus patients treated conservatively. – This difference is reflected in patients >65 yrs of age. –There is no statistically significant difference in in- hospital mortality in patients younger than 65 yrs. –There is statistically significant difference in in- hospital mortality in males, patients with ischemic changes on EKG and patients having more than 3 risk factors.

Primary Outcome Characteristic No of Patients Early % Delayed % Odd’s ratio for event(95%CI)P-Value for Interaction Overall ( to ) Age < ( to ) > ( to ) Sex Female ( to ) Male (0.204 to ) ST segment deviation No Yes ( to ) Revascularized No ( to ) Yes ( to )

Results Primary End-Point - No statistically significant difference in in-hospital mortality in patients treated with early revascularization versus patients treated with delayed vascularization

Secondary Outcome Variable Early Revascularization Delayed Revascularization P value Medical Management P value* Length of Stay Mean Age> Bleeding Complications % Acute Stroke % Acute Renal Failure %

Results Secondary Outcome –Statistically significant difference in hospital length of stay in patients treated with re vascularization versus patients treated conservatively –Statistically significant difference in hospital length of stay in patients treated with early revascularization versus patients treated with delayed revascularization. –Statistically significant difference in hospital length of stay in patients >65 years treated with revascularization versus patients treated conservatively.

Conclusion Revascularization offers benefit in reducing short term mortality over medical therapy alone Benefit is more pronounced in elderly high risk male patients. Immediate catheterization and intervention does not offer a benefit over initial medical stabilization followed by delayed catheterization and intervention

How are we doing? Comparison with Action registry data

Comparative Data with GWTG Action Registry for 2010 Characteristic % 2010 % Odd’s ratio for event(95%CI)P-Value for Interaction Nation Top10% Unadjusted Death ( to ) Risk Adjusted Death (0.413 to ) Bleeding Events (0.36 to 2.778) 18 Medications Aspirin ( to ) Clopidogrel ( to ) Prasugrel - 47 Revascularization overall ( to ) Within 24 hrs ( to ) Catheterization Within 24 hrs ( to )

Thinking outside the box…

References 1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361: Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005; 293: Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, 3.Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006;48: Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283: Antman EM, Hand M, Armstrong PW, et al Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008;117: [Erratum, Circulation 2008;117(6):e162.] 6.Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326: Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344: Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354: Fox KA, Poole-Wilson P, Clayton TC, et al. 5-Year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005;366: Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/angioplasty in evolving non-ST segment elevation myocardial infarction: an open multicenter randomized trial. Eur Heart J 2002;23: Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003;290: de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005;353: Riezebos RK, Ronner E, Ter Bals E, et al. Immediate versus deferred coronary angioplasty in non-ST-elevation acute coronary syndromes. Heart 2008 December Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009;360: